Sun BioPharma, Inc. (OTCMKTS:SNBP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2017 Annual Meeting of Shareholders of Sun BioPharma, Inc.
(the Company) was held on June 6, 2017. The final results of the
shareholder vote on each proposal brought before the Annual
Meeting were as follows:
|
For |
Withhold |
Broker Non-Votes |
|||||||||||
|
Proposal No. 1 Election of class 1 directors |
|||||||||||||
|
Suzanne Gagnon |
23,607,922 | 1,025 | |||||||||||
|
David B. Kaysen |
19,893,678 | 3,715,269 | |||||||||||
|
Paul W. Schaffer |
23,338,947 | 270,000 | |||||||||||
|
For |
Against |
Abstain |
Broker Non-Votes |
|||||||||||||
|
Proposal No. 2Ratification of the selection of Cherry |
24,756,912 | 140,000 | ||||||||||||||
All proposals were approved by the Companys shareholders by the
required vote.
About Sun BioPharma, Inc. (OTCMKTS:SNBP)
Sun BioPharma, Inc., formerly Cimarron Medical, Inc., is a clinical stage drug development company. The Company is a biopharmaceutical company focused on developing therapies for pancreatic diseases. It is engaged in the commercial development of a polyamine analogue for pancreatic cancer and for a second indication in chronic pancreatitis. The Company’s products include SBP-101, SBP-102 and SBP-103. Its SBP-101 is a polyamine compound and exhibits specificity for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. It develops SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma. The SBP-102 product is in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. The SBP-103 product is in non-clinical exploratory evaluation. The Company has enrolled first patient in its Phase I clinical trial of SBP-101 in patients with previously treated pancreatic cancer.
